Literature DB >> 26980727

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Steven H Swerdlow1, Elias Campo2, Stefano A Pileri3, Nancy Lee Harris4, Harald Stein5, Reiner Siebert6, Ranjana Advani7, Michele Ghielmini8, Gilles A Salles9, Andrew D Zelenetz10, Elaine S Jaffe11.   

Abstract

A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26980727      PMCID： PMC4874220          DOI： 10.1182/blood-2016-01-643569

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  154 in total

1.  Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans' cell sarcoma: evidence for hematopoietic plasticity.

Authors:  Richard Ratei; Michael Hummel; Ioannis Anagnostopoulos; Doris Jähne; Renate Arnold; Bernd Dörken; Stephan Mathas; Thomas Benter; Oliver Dudeck; Wolf-Dieter Ludwig; Harald Stein
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

3.  Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma?

Authors:  Tony Petrella; Eve Maubec; Pascale Cornillet-Lefebvre; Rein Willemze; Michel Pluot; Anne Durlach; Eduardo Marinho; Jean-Luc Benhamou; Patty Jansen; Alistair Robson; Florent Grange
Journal:  Am J Surg Pathol       Date:  2007-12       Impact factor: 6.394

4.  Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma.

Authors:  Sylvia Hartmann; Claudia Döring; Emily Vucic; Fong Chun Chan; Daisuke Ennishi; Thomas Tousseyn; Christiane de Wolf-Peeters; Sven Perner; Iwona Wlodarska; Christian Steidl; Randy D Gascoyne; Martin-Leo Hansmann
Journal:  Br J Haematol       Date:  2015-02-02       Impact factor: 6.998

5.  Chronic lymphocytic leukemia/small lymphocytic lymphoma with cyclin D1 positive proliferation centers do not have CCND1 translocations or gains and lack SOX11 expression.

Authors:  Joel F Gradowski; Rachel L Sargent; Fiona E Craig; Kathleen Cieply; Kim Fuhrer; Carol Sherer; Steven H Swerdlow
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

6.  Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.

Authors:  Raju K Pillai; Urvashi Surti; Steven H Swerdlow
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

Review 7.  B-cell receptor signaling in diffuse large B-cell lymphoma.

Authors:  Ryan M Young; Arthur L Shaffer; James D Phelan; Louis M Staudt
Journal:  Semin Hematol       Date:  2015-01-15       Impact factor: 3.851

8.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  ID3 mutations are recurrent events in double-hit B-cell lymphomas.

Authors:  Niklas Gebauer; Veronica Bernard; Alfred C Feller; Hartmut Merz
Journal:  Anticancer Res       Date:  2013-11       Impact factor: 2.480
View more
  1729 in total

1.  Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

Authors:  Onyemaechi N Okolo; Ariel C Johnson; Seongseok Yun; Stacy J Arnold; Faiz Anwer
Journal:  Immunotherapy       Date:  2017-08-03       Impact factor: 4.196

Review 2.  [Diagnostics of primary cutaneous lymphomas].

Authors:  M Felcht; U Hillen; C-D Klemke
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

3.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Parth A Desai; Pei Lin; Jason R Westin; Huda M Hawsawi; Peng Wei; Guilin Tang; Adam C Seegmiller; Nishitha M Reddy; C Cameron Yin; Wei Wang; Jie Xu; Roberto N Miranda; Zhuang Zuo; Shaoying Li
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 4.  Breast Implant-Associated Anaplastic Large-Cell Lymphoma: Current Understanding and Recommendations for Management.

Authors:  Tessa L St Cyr; Barbara A Pockaj; Donald W Northfelt; Fiona E Craig; Mark W Clemens; Raman C Mahabir
Journal:  Plast Surg (Oakv)       Date:  2020-05-21       Impact factor: 0.947

5.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

6.  Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Authors:  J Chen; V Mehraj; J Szabo; B Routy; R P Michel; J P Routy
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 8.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

9.  A case of HTLV-1 associated adult T-cell lymphoma presenting with cutaneous lesions and tropical spastic paresis.

Authors:  Purva V Sharma; Michael Witteman; Swethika Sundaravel; Tulisa Larocca; Yuanming Zhang; Harry Goldsztajn
Journal:  Intractable Rare Dis Res       Date:  2018-02

10.  Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation.

Authors:  Moozhan Nikpanah; Lauren Kim; S Mojdeh Mirmomen; Rolf Symons; Ioannis Papageorgiou; William A Gahl; Kevin O'Brien; Juvianee I Estrada-Veras; Ashkan A Malayeri
Journal:  Eur Radiol       Date:  2018-03-19       Impact factor: 5.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.